115195
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
基于巨噬细胞膜包覆 Fe3O4 纳米颗粒的仿生纳米平台用于肺癌铁死亡和声动力协同治疗
Authors Zhang H, Zhuang Y, Song J, Shao F , Shi W
Received 10 October 2025
Accepted for publication 30 December 2025
Published 13 January 2026 Volume 2026:21 573349
DOI https://doi.org/10.2147/IJN.S573349
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Eng San Thian
Hongming Zhang,1,* Yu Zhuang,2,* Jianxiang Song,3 Feng Shao,2 Woda Shi3
1Department of Pneumology, Affiliated Hospital 6 of Nantong University, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People’s Hospital, Yancheng, Jiangsu, 224000, People’s Republic of China; 2Department of Thoracic Surgery, Nanjing Chest Hospital, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210029, People’s Republic of China; 3Department of Cardiothoracic Surgery, Affiliated Hospital 6 of Nantong University, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People’s Hospital, Yancheng, Jiangsu, 224000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Feng Shao, Nanjing Chest Hospital, Affiliated Nanjing Brain Hospital, Nanjing Medical University, No. 215 Guangzhou Road, Nanjing, 210029, People’s Republic of China, Email doctorshao1982@sina.com Woda Shi, Department of Cardiothoracic Surgery, Affiliated Hospital 6 of Nantong University, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People’s Hospital, No. 75 Juchang Road, Yancheng, Jiangsu, 224000, People’s Republic of China, Email xuelangziyao@163.com
Introduction: Triiron tetraoxide nanoparticles (Fe3O4 NPs) effectively induce ferroptosis. However, they are readily identified as foreign by the immune system and undergo rapid clearance from the body via the reticuloendothelial system. Macrophages are a type of phagocytic immune cell. They identify and engulf cancer cells and any foreign entities that lack the specific surface biomarkers of healthy somatic cells. Studies have proposed that camouflaging NPs with macrophage membranes enables effective cancer targeting via cell-cell adhesion mechanisms.
Methods: Therefore, we harvested vesicles derived from macrophage membranes and coated them onto the surface of Fe3O4 nanoparticles. This formed a core-shell, biomimetic nanodrug delivery system: Fe3O4@MPs. Subsequently, we loaded hematoporphyrin monomethyl ether (HMME) onto this platform (Fe3O4-HMME@MPs). The nanoparticles were comprehensively characterized. Their in vitro performance, including cellular uptake, reactive oxygen species generation, ferrous ions (Fe2+) release, and cytotoxicity, was evaluated using A549 lung cancer cells. For in vivo studies, a subcutaneous xenograft model was established in nude mice using A549 cells. The tumor-targeting ability was assessed via fluorescence imaging, and the therapeutic efficacy was systematically evaluated by monitoring tumor volume/weight, histopathological analysis, and immunohistochemical staining (Perls-DAB, TUNEL, Ki67, GPX4).
Results: Characterization of the NPs, along with in vivo and in vitro experiments, confirmed that Fe3O4-HMME@MPs possess excellent biocompatibility, immune evasion capabilities, and effective targeting of lung tumors. Fe3O4-HMME@MPs treat solid lung tumors through a synergistic of ferroptosis and Sonodynamic therapy.
Conclusion: Our platform provides us with a novel biomimetic strategy, offering a promising approach for clinical translation in lung cancer therapy.
Keywords: triiron tetraoxide nanoparticles, sonodynamic therapy, lung cancer, ferroptosis, macrophage membrane
1Department of Pneumology, Affiliated Hospital 6 of Nantong University, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People’s Hospital, Yancheng, Jiangsu, 224000, People’s Republic of China; 2Department of Thoracic Surgery, Nanjing Chest Hospital, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210029, People’s Republic of China; 3Department of Cardiothoracic Surgery, Affiliated Hospital 6 of Nantong University, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People’s Hospital, Yancheng, Jiangsu, 224000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Feng Shao, Nanjing Chest Hospital, Affiliated Nanjing Brain Hospital, Nanjing Medical University, No. 215 Guangzhou Road, Nanjing, 210029, People’s Republic of China, Email doctorshao1982@sina.com Woda Shi, Department of Cardiothoracic Surgery, Affiliated Hospital 6 of Nantong University, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People’s Hospital, No. 75 Juchang Road, Yancheng, Jiangsu, 224000, People’s Republic of China, Email xuelangziyao@163.com
Introduction: Triiron tetraoxide nanoparticles (Fe3O4 NPs) effectively induce ferroptosis. However, they are readily identified as foreign by the immune system and undergo rapid clearance from the body via the reticuloendothelial system. Macrophages are a type of phagocytic immune cell. They identify and engulf cancer cells and any foreign entities that lack the specific surface biomarkers of healthy somatic cells. Studies have proposed that camouflaging NPs with macrophage membranes enables effective cancer targeting via cell-cell adhesion mechanisms.
Methods: Therefore, we harvested vesicles derived from macrophage membranes and coated them onto the surface of Fe3O4 nanoparticles. This formed a core-shell, biomimetic nanodrug delivery system: Fe3O4@MPs. Subsequently, we loaded hematoporphyrin monomethyl ether (HMME) onto this platform (Fe3O4-HMME@MPs). The nanoparticles were comprehensively characterized. Their in vitro performance, including cellular uptake, reactive oxygen species generation, ferrous ions (Fe2+) release, and cytotoxicity, was evaluated using A549 lung cancer cells. For in vivo studies, a subcutaneous xenograft model was established in nude mice using A549 cells. The tumor-targeting ability was assessed via fluorescence imaging, and the therapeutic efficacy was systematically evaluated by monitoring tumor volume/weight, histopathological analysis, and immunohistochemical staining (Perls-DAB, TUNEL, Ki67, GPX4).
Results: Characterization of the NPs, along with in vivo and in vitro experiments, confirmed that Fe3O4-HMME@MPs possess excellent biocompatibility, immune evasion capabilities, and effective targeting of lung tumors. Fe3O4-HMME@MPs treat solid lung tumors through a synergistic of ferroptosis and Sonodynamic therapy.
Conclusion: Our platform provides us with a novel biomimetic strategy, offering a promising approach for clinical translation in lung cancer therapy.
Keywords: triiron tetraoxide nanoparticles, sonodynamic therapy, lung cancer, ferroptosis, macrophage membrane